Growth Hormone Releasing Peptide-2 Boosts Appetite and Gut Activity in Dogs
Background
Growth Hormone Releasing Peptide-2 (GHRP-2) is a synthetic ghrelin mimetic, meaning it acts like the natural "hunger hormone" ghrelin. It's known to stimulate the release of growth hormone and increase appetite. While its orexigenic (appetite-stimulating) effects are well-documented, the precise impact of GHRP-2 on upper gastrointestinal contractile activity and its direct correlation with food intake in conscious dogs remained unclear. This study aimed to elucidate these specific physiological responses.
Results
The study revealed that GHRP-2 significantly modulated both gastrointestinal motility and food intake. At the 30 µg/kg dose, GHRP-2 led to a 2.5-fold increase in the frequency of antral contractions compared to saline control (p<0.01), indicating enhanced gastric emptying potential. Duodenal and jejunal motility also showed a 1.8-fold increase in contractile amplitude (p<0.05) with the higher dose. These changes in motility and appetite were observed within 60 minutes of administration, peaking around 90 minutes. The most striking finding was the substantial increase in food intake, with dogs receiving 30 µg/kg GHRP-2 consuming 145% more food than the saline control group (p<0.001), averaging 450 grams versus 184 grams. Even the lower 10 µg/kg dose resulted in a 78% increase in food consumption (p<0.05), demonstrating a dose-dependent orexigenic effect.
Why It Matters
This research provides crucial insights into the dual action of GHRP-2, confirming its potent ability to both stimulate appetite and enhance upper gastrointestinal motility in a large animal model. The strong orexigenic effect combined with improved gut function suggests GHRP-2 could be a promising therapeutic agent for conditions characterized by anorexia and cachexia, such as cancer-related wasting or chronic kidney disease. Further investigation in human clinical trials, particularly Phase II studies, is warranted to explore its efficacy and safety in patients struggling with severe appetite loss and malnutrition. This could pave the way for novel treatments to improve nutritional status and quality of life.